About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Docs on Twitter


Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Innogenetics v. Abbott Labs. (W.D. Wis. 2007) | Main | Setback for Ariad in Dispute with Amgen »

January 09, 2007

Genentech and Seattle Genetics Enter Agreement

    By Jason Derry --

Genentech Genentech and Seattle Genetics have announced an agreement involving the development and commercialization of a humanized monoclonal antibody for treating hematologic malignancies, including multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma.  The antibody, SGN-40, is currently in Phase I and II clinical trials.  According to the press release, Seattle Genetics will receive $60 million in up-front payment, and may receive more than $800 million in milestone payments and increasing royalties on sales of SGN-40 in the future.

Seattle Genetics Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.

Posted at 09:23 AM in Biotech/Pharma Business, Licensing |

Comments

The comments to this entry are closed.

September 2021

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30    

Categories

Archives

More...